• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by GENFIT S.A.

    5/7/25 4:10:07 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNFT alert in real time by email
    6-K 1 f6k_050725.htm FORM 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    Date of report: May 7, 2025

    Commission File Number: 001-38844

    GENFIT S.A.

    (Translation of registrant’s name into English)

     

    Parc Eurasanté

    885, avenue Eugène Avinée

    59120 Loos, France

     

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    ☒ Form 20-F ☐ Form 40-F

     

     

    Explanatory Note

     

    General Meeting

     

    Genfit S.A. (the “Company”) will hold its Combined Shareholders’ Meeting (the “Meeting”) on June 17, 2025 beginning at 10 a.m. CEST at the Faculté de Pharmacie de Lille located at Parc Eurasanté, 3 rue du Professeur Laguesse in Lille (59000), France.

     

    Additional information regarding the Meeting is available to shareholders on the Company’s website, in the Investors & Media section (https://ir.genfit.com/financial-information/shareholders-meeting).

     

    The following documents regarding the Company’s Meeting, which are attached as exhibits hereto, are incorporated by reference herein.

     

     

     

     

     

     

    EXHIBIT LIST

     

    Exhibit

     

    Description

       
    99.1   Press Release dated May 7, 2025.
       
    99.2   Notice of the combined shareholder meeting

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      GENFIT S.A.
         
    Date: May 7, 2025 By:   /s/ Pascal PRIGENT
          Name: Pascal PRIGENT
          Title: Chief Executive Officer

     

    Get the next $GNFT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNFT

    DatePrice TargetRatingAnalyst
    8/19/2025$9.00Buy
    H.C. Wainwright
    12/20/2021$8.00Neutral → Buy
    HC Wainwright & Co.
    9/30/2021$8.00 → $7.00Neutral
    HC Wainwright & Co.
    More analyst ratings

    $GNFT
    SEC Filings

    View All

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    7/8/25 4:10:11 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    6/17/25 2:50:04 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GENFIT S.A.

    6-K - Genfit S.A. (0001757064) (Filer)

    5/22/25 4:10:12 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Genfit with a new price target

    H.C. Wainwright resumed coverage of Genfit with a rating of Buy and set a new price target of $9.00

    8/19/25 8:33:55 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genfit upgraded by HC Wainwright & Co. with a new price target

    HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00

    12/20/21 6:28:59 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on Genfit with a new price target

    HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously

    9/30/21 6:11:01 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

    Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic

    5/31/23 4:44:00 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

    Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

    12/17/21 1:00:00 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNFT
    Financials

    Live finance-specific insights

    View All

    Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

    Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

    12/17/21 1:00:00 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

    SC 13G/A - Genfit S.A. (0001757064) (Subject)

    2/14/24 4:00:25 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by GENFIT S.A.

    SC 13G - Genfit S.A. (0001757064) (Subject)

    5/1/23 4:00:10 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

    SC 13G/A - Genfit S.A. (0001757064) (Subject)

    2/14/22 6:28:17 AM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care